FOSUN HEALTH Logo

Lung Cancer Diagnosis

catalogue

Lung Cancer Diagnosis

Lung Cancer Diagnosis

A clear answer in days, not months — and it is not just about naming the disease. Diagnosis decides which treatments can work for you, so the tests matter as much as the result.

Step 1: Imaging — finding it and mapping it

Everything begins with pictures. Which scan you need depends on whether we are screening a person at risk, investigating a symptom, or mapping a known tumor.

Low-dose CT (LDCT)

The screening test. It detects nodules smaller than a fingernail, years before symptoms, and uses only a modest radiation dose — far less than a conventional CT. For people at higher risk it is the single most effective way to find lung cancer while cure is still likely.

Contrast-enhanced CT

Shows the nodule's exact size, shape and density, and whether lymph nodes in the chest are enlarged. This is the scan that decides whether a nodule looks stable, suspicious, or clearly requires tissue sampling.

PET-CT

A whole-body scan that shows metabolic activity — how "hungry" the tissue is. It helps tell a benign scar from an active tumor, and reveals whether the disease has spread to lymph nodes, bone, liver or elsewhere. Both scanners are in-house at our hospitals, so there is no outsourcing delay.

Brain MRI

Added when the tumor type or stage makes spread to the brain a realistic possibility, since the brain is a common site of spread that CT does not assess well.

Step 2: Tissue — confirming it is cancer

Imaging can raise suspicion, but only tissue proves it. A biopsy also gives us the material every later decision depends on.

Bronchoscopy

A thin, flexible scope passes through the mouth and airway, under light sedation. It reaches tumors near the centre of the lung and can sample lymph nodes at the same time using ultrasound guidance (EBUS) — often the most efficient single test when glands are involved.

CT-guided needle biopsy

For tumors near the outer edge of the lung, a fine needle is guided through the chest wall under CT, with local anesthetic. It takes about 30 minutes; you may feel pressure rather than pain, and you are observed afterwards to check for complications such as a small collapsed lung.

Some patients are anxious that a biopsy will "wake up" or spread the cancer. That concern is not supported — the procedure is the standard of care worldwide, and the information it provides is what makes precise, less invasive treatment possible.

Step 3: Pathology — what kind of lung cancer is it

Lung cancer is not one disease. Two families behave very differently, and the distinction changes treatment from the first day:

Non-small cell lung cancer (NSCLC)

About 85% of cases. The common subtypes are adenocarcinoma (most frequent, often in the outer lung, and common in never-smokers), squamous cell carcinoma (usually near the central airways), and large cell carcinoma. NSCLC is the group where surgery, radiosurgery, targeted drugs and immunotherapy all play major roles.

Small cell lung cancer (SCLC)

Less common, faster-growing and more likely to have spread by the time it is found. It is treated mainly with chemotherapy and radiotherapy, with immunotherapy added in many cases. Because it behaves so differently, identifying it correctly is essential.

Pathology also reports how the tumor looks under the microscope and whether surgical margins are clear in removed specimens — details that later guide both treatment and follow-up.

Step 4: Molecular profiling — what is driving the cancer

For NSCLC, we test the tumor's genetics because a targeted drug only works when its target is present. This is where precision oncology actually begins.

Driver mutations — EGFR, ALK, ROS1, MET, RET

These alterations are more common in East Asian patients, particularly in never-smokers. If one is present, a matching oral targeted drug can control the disease with fewer side effects than chemotherapy.

PD-L1 expression

Measures a protein that predicts how likely you are to respond to immunotherapy. It is read alongside the mutation results, not instead of them.

NGS (next-generation sequencing)

Tests many genes at once from a single tissue sample, and can also be done from a blood sample (liquid biopsy) when tissue is limited or a repeat biopsy is not practical.

If your biopsy was performed elsewhere and molecular testing was not done, or was done on an older platform, ask for the tissue block to be re-examined. Missing a treatable mutation is one of the most common reasons a patient is offered chemotherapy when a targeted drug would have been a better first choice.

Step 5: Staging — how far has it gone

Staging summarises the tumor's size and local extent (T), lymph node involvement (N), and spread to distant organs (M). In plain terms:

StageWhat it meansTypical treatment direction
Stage ISmall tumor confined to the lung, no node involvementSurgery, or radiosurgery when surgery is not suitable — both with cure as the aim
Stage IILarger tumor, or cancer in nearby lymph nodes on the same sideSurgery, usually with additional drug therapy; radiosurgery in selected cases
Stage IIILocally advanced — tumor involving central structures or nodes on both sides of the chestCombined treatment: chemotherapy with radiation or immunotherapy, sometimes followed by surgery
Stage IVCancer has spread beyond the chestTargeted therapy, immunotherapy or chemotherapy; radiotherapy and interventional treatments for control of specific sites

Stage is not the only deciding factor. We also score your lung function and general fitness, because the most effective treatment is only useful if your body can tolerate it — and because protecting your breathing capacity is part of the goal, not a secondary concern.

See how each stage is treated for what these options involve in practice.

From diagnosis to a plan

When the results are in, they are not handed to a single department. Thoracic surgery, medical oncology, radiation oncology, interventional radiology, radiology and pathology review your case together and issue one unified plan — because when surgery, radiosurgery, targeted therapy and immunotherapy are all reasonable options, the choice should be made by collective judgement rather than departmental habit.

For international patients, send these so the panel can start:
  • CT, MRI and PET-CT images (DICOM files if available) or their written reports
  • Pathology and biopsy reports, including the tumor type and any molecular results
  • Laboratory results, including tumor markers and liver or kidney function
  • A list of treatments already received and how the tumor responded
  • A short summary of your main symptoms and when they started

With complete records, the panel's unified plan is returned within 48 hours.

Frequently Asked Questions

How long does it take to get a lung cancer diagnosis?

It depends on which tests a nodule needs, but at Fosun Health the pathway is completed in days rather than months: CT and PET-CT are usually done within the first days, biopsy and pathology within about a week, and molecular profiling (NGS) within one to two weeks. Because all of these run in-house, there is no waiting on external laboratories between steps.

Is a lung biopsy painful or risky?

A lung biopsy is usually done under local anesthetic and takes about 30 minutes, using either a thin scope through the airway (bronchoscopy) or a needle guided by CT from the outside of the chest. You may feel pressure rather than pain. Serious complications such as significant bleeding or a collapsed lung are uncommon, and our teams observe you afterwards and can treat them if they occur.

What does molecular testing show that imaging cannot?

Imaging shows where a tumor is and how large it is; molecular testing shows what is driving it. Testing for EGFR, ALK, ROS1, MET and RET alterations, and for PD-L1, determines whether targeted therapy or immunotherapy is likely to work for you. Without it, a treatment can look reasonable on a scan but fail because the tumor lacks the target the drug depends on.

What should international patients send for an evaluation?

Send your CT and MRI images (DICOM files if possible, or the imaging reports), PET-CT report, pathology and biopsy reports, laboratory results including tumor markers, details of any treatment you have already received, and a brief summary of your main symptoms. Complete records are what allow our multidisciplinary panel to issue a personalized plan within 48 hours.

Patient Stories

Stories from our lung cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Have your scans read by a lung cancer panel

Send your CT, PET-CT, pathology and molecular reports. Our multidisciplinary team will confirm the stage, identify any treatable mutation that may have been missed, and return a unified plan within 48 hours.

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*